FindTrial
Sign In

Theophylline ER

DRUG3 trials

Sponsors

University of Miami, Ashley Shoemaker, University of California, Los Angeles

Conditions

Albright Hereditary OsteodystrophyCOPDCOPD ExacerbationCOPD Exacerbation AcuteDepressionPollution Related Respiratory DisorderPollution; ExposurePseudohypoparathyroidism

Early Phase 1

Theophylline for Depression Study
WithdrawnNCT04309877
University of California, Los AngelesDepression
Start: 2023-03-31End: 2025-06-30Updated: 2021-11-05

Phase 2

Theophylline for Treatment of Pseudohypoparathyroidism
Enrolling by invitationNCT04240821
Ashley ShoemakerAlbright Hereditary Osteodystrophy, Pseudohypoparathyroidism, Pseudohypoparathyroidism Type 1a
Start: 2020-05-22End: 2026-12-31Target: 34Updated: 2026-02-23

Phase 3

Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated COPD
CompletedNCT03984188
University of MiamiCOPD, COPD Exacerbation, COPD Exacerbation Acute +2
Start: 2021-02-23End: 2023-12-15Updated: 2024-11-15

Related Papers

Clinical Phenotypes of Acute Exacerbations Among People With Chronic Obstructive Pulmonary Disorder in Uganda
American Journal of Respiratory and Critical Care Medicine2025-05-01
FRI597 Impact Of Theophylline On BMI In Pseudohypoparathyroidism Type 1a - Results Of An Open Label Extension Trial
Journal of the Endocrine Society2023-10-01
Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial.
2021-03-167 citations